Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2495655 in Advanced Pancreatic Cancer
NCT01505530Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2011
- Primary completion
- Oct 2014
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of landogrozumab in pancreatic cancer (PC), sponsored by Eli Lilly and Company. Started Dec 2011; status: completed.
02
Drugs
landogrozumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01505530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01505530.